Insmed Reports Strong 2025 Results, FDA Grants Orphan Drug Status to Treprostinil Palmitil
Insmed reported total revenues of $606.4 million for 2025, with ARIKAYCE growing 19% annually. The FDA granted orphan drug designation to treprostinil palmitil for pulmonary arterial hypertension treatment in January 2026.